EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) will have CEO Nancy Lurker speak at the Jefferies Healthcare Conference on June 2, 2021, at 9:30 a.m. ET. The session will explore the company's commitment to developing therapies for serious eye disorders, including innovations like EYP-1901, a treatment for wet age-related macular degeneration. Attendees can access a live webcast and a 90-day archive via EyePoint's website. The company also markets YUTIQ and DEXYCU for eye disorder treatments.

WATERTOWN, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Jefferies Healthcare Conference on June 2, 2021 at 9:30 a.m. ET.

A live webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.

About EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert^® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ^®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU^®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

Investors:

Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact

Green Room Public Relations
Caren Begun
Green Room Communications
Direct: (201) 396-8551 
caren@greenroompr.com

FAQ

When will EyePoint Pharmaceuticals' CEO Nancy Lurker speak at the Jefferies Healthcare Conference?

Nancy Lurker will speak at the Jefferies Healthcare Conference on June 2, 2021, at 9:30 a.m. ET.

How can I watch the EyePoint Pharmaceuticals fireside chat?

You can access the live webcast and archived replay of the fireside chat on EyePoint Pharmaceuticals' Investors section of their website.

What is EYP-1901 developed by EyePoint Pharmaceuticals?

EYP-1901 is a potential intravitreal anti-VEGF treatment targeting wet age-related macular degeneration, leveraging the company's Durasert technology.

What products are offered by EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals offers YUTIQ for chronic non-infectious uveitis and DEXYCU for postoperative inflammation following ocular surgery.

Where is EyePoint Pharmaceuticals headquartered?

EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.